



Invited Review

# Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes

Robert Thomas<sup>1,\*</sup>, Stacey A. Kenfield<sup>2</sup>, Yuuki Yanagisawa<sup>3</sup>, and Robert U. Newton<sup>4</sup>

<sup>1</sup>Department of Oncology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK, <sup>2</sup>Departments of Urology and Epidemiology and Biostatistics, University of California at San Francisco, Mission Hall, Box 1695-550, 16th Street, 6th Floor, San Francisco, CA 9414, USA, <sup>3</sup>Department of Medicine, Bedford Hospital, Kempston road, Bedford MK42 9DJ, UK, and <sup>4</sup>Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Perth, WA 6027, Australia

\*Correspondence address. Department of Oncology, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK.  
E-mail: [Robert.thomas@addenbrookes.nhs.uk](mailto:Robert.thomas@addenbrookes.nhs.uk)

Editorial Decision 28 July 2021; Accepted 30 July 2021

## Abstract

**Introduction:** Exercise is one of several factors known to lower the risk of developing cancer, as well as improve outcomes in patients already diagnosed. People who exercise after cancer have lower rates of cancer complications, treatment toxicities, relapse and improved survival. This review highlights the supportive data and biochemical processes, which explain these potential benefits.

**Sources of data:** PubMed, Embase, Medline and Cochrane libraries were searched for papers which addressed the effects of exercise and physical activity on cancer for this review. The search terms used were physical activity, exercise and cancer up to February 2021. We also referred to the background research required for international exercise intervention study involving men with prostate cancer (INTERVAL-GAP4) and scrutinized references within the robust papers published on this subject to ensure we

did not miss any clinically studies. One hundred and eighty eight papers were included.

**Areas of agreement:** Exercise programmes mitigate many of the complications and risks associated with cancer, particularly thromboembolism, fatigue, weight gain, arthralgia, cognitive impairment and depression.

**Areas of controversy:** Molecular and biomarker changes, resulting from exercise, suggest that exercise elicits beneficial changes in insulin-related pathways, down-regulates inflammation and serum oestrogen levels, and enhances oxidative, immune and cellular repair pathways. Nonetheless, the evidence remains preliminary.

**Growing points:** The timing, intensity and challenges of prehabilitation, adjunct and rehabilitation exercise programmes are being increasingly understood but their implementation remains sporadic.

**Areas for developing research:** More robust clinical trial data are needed to substantiate a causal effect of exercise on overall and cancer-specific survival. These studies are ongoing. Research evaluating the most cost-efficient ways of incorporating prehabilitation, adjunct and rehabilitation programmes into routine practice would be helpful to funding bodies and health care strategists.

**Key words:** exercise, cancer prevention, cancer survivorship

---

## The influence of exercise on cancer prevention

Associations between exercise and a lower risk of developing cancer have been made evident in multiple cohort studies.<sup>1-10</sup> These studies are open to habit-forming linkages as physically active people are less likely to smoke, are less likely to be overweight and consume more vegetables.<sup>1,11,12</sup> Despite these potential biases, the sheer volume of comprehensive datasets analyses conducted in different populations across the world have made legitimate efforts to adjust for other confounding lifestyle factors. This has convinced most public health bodies that exercise is one of several crucial lifestyle habits known to lower the risk of developing several different types of cancer, detailed below.<sup>13-16</sup>

For prostate cancer, a compelling analysis of the large Health Professional's Follow-up Study (HPFS) demonstrated that increased exercise levels

were associated with a significant reduction in aggressive subtypes including incident advanced and fatal prostate cancer in a prospective cohort.<sup>4</sup> With respect to breast cancer, a 2016 meta-analysis based on 38 cohort studies concluded that patients who were more physically active had a lower risk of breast cancer in comparison to those who were less physically active.<sup>17</sup> Further studies have revealed similar reductions in risk of breast cancer among both premenopausal and postmenopausal women.<sup>17-20</sup> A pooled analysis of over 1 million individuals found that leisure-time physical activity was linked to a significantly reduced risk of bladder cancer.<sup>21</sup> A separate meta-analysis found that the risk of bladder cancer was lower for individuals with the highest level of recreational or occupational physical activity versus those who were the least physically active.<sup>22</sup> In a 2016 meta-analysis of 126 studies, individuals who engaged in the highest

level of physical activity had a lower risk of colon cancer with respect to those who were the least physically active.<sup>3</sup> Similar results have been reported for prevention of uterine, oesophageal, stomach and renal cancers.<sup>8,23–28</sup>

Physical activity is defined as any bodily movement by skeletal muscles that require energy expenditure, while exercise is a sub-category of physical activity which is structured and planned specifically for the purpose of maintaining or improving fitness and health. Throughout this paper, we will use these terms somewhat interchangeably although recognizing above distinctions. Although the optimal mode and dosage of exercise has not been established and specifics vary across the literature, the consensus is that individuals who exercise at a moderate intensity level (for 3–4 hours a week) or greater have approximately a 10–20% reduction in the risk of cancer compared with sedentary individuals.<sup>13–16</sup> Furthermore, the earlier people start exercising and the greater the number of other healthy lifestyle factors a person has, the stronger the link is to a lower cancer risk.<sup>3,6,7,10,29,30</sup>

## The influence of exercise on cancer relapse and survival

The benefits of exercise do not stop following a diagnosis of cancer. Research findings show that regular exercise has potential beneficial effects on the survival of patients living with cancer, with the most robust evidence demonstrated in prostate, breast and bowel cancers.<sup>1,11,31–37</sup>

### *Breast cancer*

In 2005, an evaluation of 2987 patients in the Nurses' Health Study found that women with breast cancer who were walking more than 3 hours a week had lower recurrence rates of breast cancer and a greater overall survival.<sup>38</sup> In 2008, a cohort study of breast cancer survivors identified that patients who consistently exercised for greater than 2.5 hours per week following diagnosis had a greater than 60% reduction in the risk of all deaths compared with patients who were physically inactive.<sup>7</sup> Similar

findings were reported from other observational and cohort studies from across the world.<sup>29,39–41</sup> A 2019 systematic review of 25 563 patients concluded that breast cancer survivors who were the most physically active had a 42% lower risk of death from any cause and a 40% lower risk of death from breast cancer in comparison to patients that were the least physically active.<sup>42</sup>

### *Colorectal cancer*

In 2002, a retrospective analysis of patients who had been recruited into an Australian cohort study revealed that those participating in recreational sport for 1–2 days per week had a 5-year overall survival of 71% as opposed to a 57% survival in non-exercisers.<sup>5</sup> Likewise, in the HPFS, men with colorectal cancer who exercised regularly (>27 metabolic equivalent hours/week) had a significantly lower cancer specific mortality compared with sedentary men (<3 MET hours/week).<sup>43</sup> Other prospective cohort studies from across the world summarized in numerous meta-analyses reported a 30–60% reduction in relapse rate, disease specific and overall death in patients with colorectal cancer who undertook regular exercise.<sup>14,36,44–46</sup>

### *Prostate cancer (CaP)*

Exercise has also been shown to have a beneficial effect on tumour marker progression. In a study conducted in men with early CaP (who did not require immediate medical or surgical intervention), randomization to a formal exercise and eating well programme led to a statistically significantly lower rate of PSA progression versus standard care.<sup>47</sup> A further analysis of the HPFS reported that men undertaking 3 or more hours per week of vigorous activity had a 61% reduction in the risk of prostate-specific death compared with men who undertook vigorous activity for less than 1 hour per week.<sup>1</sup> Men who exercised vigorously 3 or more hours per week after diagnosis or men who undertook vigorous exercise both pre- and post-diagnosis had even greater reductions in all-cause mortality. This dose-effect relationship was supported by a separate prospective

**Table 1** Direct biochemical changes related to exercise

Class of effect	Effector molecule	Effect of exercise on effector molecule
Cell growth regulators	IGF1	Decreased levels
	IGFBP3	Increased levels
Proteins involved in DNA damage repair	BRCA1	Increased expression
	BRCA2	Increased expression
Epigenetic expression	RAS family oncogenes	Suppressed activity
Regulators of apoptosis and cell cycle arrest	P53	Enhanced activity
	Heat shock proteins	Enhanced activity
Hormones	Oestrogen	Reduced activity
	Testosterone	Transient increased then reduced activity
	VIP	Transient increased then reduced activity
	Leptin	Reduced activity
	Irisin	Enhanced activity
	Resistin	Reduced activity
Immune system components	NK cells	Enhanced activity
	White cell function	Enhanced activity
	White cells	Increased circulating proportion
Inflammation	C-reactive protein, interleukin-6, TNF $\alpha$	Reduced activity
	Prostaglandins	Reduced activity
	Cox-2	Reduced activity
Oxidative stress and antioxidant pathways	Glutathione, Catalase and Superoxide dismutase	Increased activity

cohort study conducted in 2011, which found that men with prostate cancer walking more than 3 hours a week was associated with an improved survival, but only if they tended to walk more than 3 miles per hour.<sup>11</sup>

### The anti-cancer underlying mechanisms of exercise

A change in the chemical environment of blood after exercise was first highlighted in 2005 within a randomized controlled trial (RCT) involving men with prostate cancer. Serum taken from patients who undertook moderate and regular exercise (30-minutes walking per day for 6 days a week) had

an almost eight times greater inhibitory effect on the growth of cultured androgen dependent prostate cancer cells compared with serum from patients in the control group.<sup>47</sup> Since then, researchers have demonstrated an array of direct biological, epigenetic, metabolic and inflammatory changes which occur in the body after exercise, both acutely and chronically.<sup>44,48</sup> The most likely direct (Table 1) and indirect (Table 2) candidates to explain the anti-cancer effects of exercise are now highlighted.

#### *Obesity, oestrogen, leptin and weight reduction*

Unwelcomed weight gain is common after breast cancer. Likewise, in a study of 440 prostate cancer

**Table 2** Indirect biological benefits of exercise

Associated activity	Effector molecule or pathway	Effect
Sunlight exposure	Vitamin D Circadian rhythm	Higher Improved
Weight loss	Oestrogen Leptin Triglycerides/Cholesterol	Lower Lower Lower
Mood	Endorphins Monoamines	Increased release Higher levels

survivors, 63% were overweight or obese.<sup>49</sup> Regardless of the reasons for weight gain, meta-analyses have demonstrated that individuals who gain weight after cancer treatments have more frequent and severe complications and worse survival.<sup>50</sup> One reason for this is the neuropeptide cytokine leptin and oestrogen, which are both generated in fat cells, particularly in postmenopausal women.<sup>51,52</sup> Leptin is known to directly promote breast cancer by enhancing angiogenesis and cell proliferation, as well as indirectly through involvement with the oestrogen and insulin signalling pathways.<sup>53</sup> This explains the links between higher levels of leptin, adiposity and hormone-related cancers such as breast and ovarian.<sup>44,54–58</sup> Conversely, the serum concentration of other adipokines cytokines (adiponectin) is inversely correlated with adiposity and breast cancer risk, probably as a result of their anti-inflammatory properties.<sup>59,60</sup>

Studies have shown that targeted exercise programmes help individuals to lose weight.<sup>35,61</sup> It is unlikely, however, that a reduction in adiposity is a major anti-cancer mechanism because exercise programmes, at best, usually only show a modest reduction in weight.<sup>61–64</sup> However, even before weight reduction occurs, exercise directly lowers serum oestrogen and leptin levels and raises adiponectin levels, independent of weight loss.<sup>63,65–67</sup> In one clinical study, this was quantified as every 100 minutes of exercise leading to a 3.6% reduction in serum oestrogen.<sup>68</sup>

### *Testosterone*

Testosterone can alter after exercise depending on the underlying level of fitness, age, exercise intensity and even mood at the time of training.<sup>69</sup> It is documented that testosterone increases immediately after vigorous exercise in some but not all studies.<sup>69–73</sup> This could be a potential concern as excess levels are associated with a higher incidence of prostate cancer.<sup>54</sup> In general, the increase in serum testosterone appears to be very short lived, lasting for 20–60 minutes post-exercise, with serum testosterone returning to pre-exercise levels by 2 hours.<sup>69–71,74,75</sup> The binding protein also rises with exercise; hence, the concentration of free and biologically active testosterone changes by very little.<sup>76</sup> Moreover, this transient testosterone rise has not been reported in older men, when they are at increased risk of prostate cancer.<sup>72,73</sup> Furthermore, over time regular moderate or intense exercise actually lowers testosterone as well as Luteinising Hormone and Follicle Stimulating Hormone due to negative feedback, which can be a symptomatic issue for younger highly trained athletes.<sup>69–71,77–79</sup> On the other hand, further research has identified that a healthy lifestyle, including exercise, delays the natural age-related decline in testosterone especially in those with obesity, metabolic syndrome, diabetes and dyslipidaemia.<sup>80</sup> Chronically, lower levels of testosterone have actually been linked to a higher risk of prostate cancer.<sup>81</sup>

### *Vitamin D levels and sunlight exposure*

Vitamin D levels and sunlight exposure are both higher in patients who exercise regularly in the open air.<sup>82</sup> Vitamin D influence on the incidence and progression of cancer is thought to be due to its effect on cell differentiation, proliferation and apoptosis.<sup>83–86</sup> Although low vitamin D levels are linked to higher relapse rates after colorectal, breast and prostate cancer,<sup>87–91</sup> no direct causal link has been established. In addition, correcting Vitamin D levels with supplementation has not demonstrated any significant effect on the incidence and progression of cancer. Daylight exposure, independent of vitamin D levels, is linked to a lower incidence of CaP.<sup>92</sup> It has been postulated that sunlight exposure may have other benefits such as modulation of the immune system and the circadian rhythm.<sup>93</sup>

### *Insulin-like growth factor (IGF-1), energy metabolism and insulin resistance*

After binding to its tyrosine kinase receptor, IGF-1 activates several signalling pathways, leading to the inhibition of apoptosis and the promotion of cell growth and angiogenesis.<sup>94,95</sup> Raised levels of IGF-1 are expected to increase tumour growth, a phenomenon which has been demonstrated in many studies together with a greater cancer risk.<sup>96,97</sup> An inverse relationship is reported with IGF binding protein (IGFBP3) levels, although this effect has not been confirmed in all studies.<sup>97</sup> Exercise has been shown to increase the levels of IGFBP3 and lower IGF-1 in a large prospective cohort study in which participants experienced a >40% reduction of cancer deaths.<sup>44</sup> Conversely, lower levels of IGF-1 in active patients have been linked to an improved survival.<sup>55</sup>

RCTs have shown that physical activity improves insulin sensitivity and glucose metabolic pathways and helps prevent weight gain especially after androgen deprivation therapy for CaP.<sup>98–100</sup> Hyperglycaemia and hyperinsulinemia secondary to insulin resistance are associated with an increased risk of cancer, poorer prognosis and higher risk of relapse

after initial treatment.<sup>55,95,97,101,102</sup> Moreover, high levels of C-peptide, a marker of insulin secretion, are associated with a more than 2-fold increased risk of CaP mortality.<sup>103</sup> One additional factor for these worse outcomes may be a hormone called resistin, also known as adipose tissue-specific secretory factor (ADSF), which is a cysteine-rich adipose-derived hormone that increases with insulin resistance. Resistin is known to up-regulate pro-inflammatory cytokines, which act via the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway to increase transcription of proteins involved in cell inflammation, proliferation and anti-apoptosis pathways.<sup>104–106</sup> Men commencing androgen deprivation therapy exhibit a rise in circulating insulin, and this hyperinsulinemia precedes changes consistent with metabolic syndrome, including adiposity, hyperlipidaemia and sarcopenia.<sup>102,107</sup>

### *DNA repair and epigenetic effects on gene expression*

Exercise has been shown to influence gene expression, yet it remains unknown how these epigenetic changes have the most influence on cancer risk.<sup>9</sup> The GEMINAL study, is a trial involving men with low-risk prostate cancer, found a set of RAS family oncogenes (*RAN*, *RAB14* and *RAB8A*) to be down-regulated after a regular exercise and lifestyle initiative.<sup>107</sup> Within prostate tissue, *RAN* (Ras-related nuclear protein) has been shown to function as an androgen receptor co-activator.<sup>107</sup> Studies involving men on active surveillance for prostate cancer showed that >180 genes had altered expression comparing those who exercised vigorously as opposed to sedentary men.<sup>108</sup> Genes especially relevant to exercise were those supporting DNA repair such as *BRCA1* and *BRCA2*, those involved in signalling cell cycling and those in the histone deacetylase pathways. The up-regulation of *BRCA* genes after activity has been highlighted in the rat mammary gland and also clinically in women who were *BRCA 1, 2* mutation carriers.<sup>109,110</sup> Markers of an improved cellular repair process were also reported in a study which showed that exercise

up-regulated the key regulator gene p53 and, by doing so, encourages damaged cells to repair or if not possible, self-destruct.<sup>109,111</sup> Telomere length was also shown to be a prognostic marker among men with CaP on active surveillance. Men taking a moderate exercise and healthy eating programme had increased nuclear telomere length compared with sedentary men and this correlated with reduced PSA progression.<sup>112</sup>

### *Oxidative stress and antioxidant pathways*

Physical activity, especially if strenuous, produces reactive oxidative species (ROS). At high concentrations, ROS are known to increase oxidative stress on DNA.<sup>113,114</sup> In a biofeedback reaction to this brief rise in ROS, especially after regular training, an adaptive up-regulation of antioxidant genes occurs resulting in greater formation of antioxidant enzymes such as glutathione, superoxide dismutase and catalase.<sup>115,116</sup> In a pilot study from California, men who reported  $\geq 3$  hours per week of vigorous exercise had modulated expression of the nuclear factor erythroid 2-related factor 2 (Nrf-2)-mediated oxidative stress response pathway in their prostate tissue compared with men who undertook less exercise.<sup>108</sup> Other studies have confirmed that trained individuals have greater levels of anti-oxidant enzymes which would potentially strengthen their defence against environmental and ingested oxidating carcinogens.<sup>115,117–119</sup> If nutritional deficiencies exist that impair the production of antioxidant enzymes, there is a danger that strenuous exercise could do more harm than good especially in the elderly, where this adaptive process is known to be attenuated.<sup>119</sup> It is important, therefore, that attention is given to nutritionally healthy foods that also help enhance up-regulation of anti-oxidant enzymes.<sup>115,117–119</sup>

### *Immunity function*

After physical activity, higher levels of catecholamines are produced, which then encourage the recruitment of leucocytes into the peripheral blood. This up-regulates the concentration of lymphocytes and

neutrophils, including natural killer (NK) cells, CD4+ T cells and B cells, potentially reducing an infection risk.<sup>120,121</sup> This observation was supported by a study which showed that individuals who regularly took more than 2 hours of moderate exercise per day has nearly 30% reduction in risk of upper respiratory tract infections compared with those with more sedentary habits.<sup>122</sup> It must be noted, however, that if exercise is too strenuous for an individual, it is followed by a transient decrease in lymphocyte concentration and impaired cellular-mediated immunity, which could potentially increase the infection risk especially after ultra-endurance running events.<sup>123</sup> Overall, most long-term studies suggest that the effect of moderate exercise has little influence on immune function in healthy populations, but its benefits are particularly relevant in the elderly, who commonly suffer from declining immune function.<sup>124,125</sup> This also implies a potential benefit for the immune function of individuals after chemotherapy; however, these studies have not yet been conducted, although preclinical research is promising.<sup>115</sup>

### *Chronic inflammation and prostaglandins*

An appropriate inflammatory response is an important part of healthy immunity but persistent and low-grade chronic inflammatory activity is associated with degenerative diseases such as atherosclerosis Alzheimer's disease and cancer.<sup>100,126</sup> There is a general consensus that over-compensation from an ailing immune system trying to maintain immunosenescence.<sup>123–125</sup> In these groups, attenuated IL-2 production leads to a decreased cytotoxic capacity of NK cells and T lymphocytes on a 'per cell' basis. To compensate for this, higher levels of inflammatory cytokines stimulate Tumour Necrosis Factor, interleukin-6 and acute phase proteins, in an attempt to increase concentrations of NK cells and T-cells.<sup>123–125,127,128</sup> These inflammatory cytokines unfortunately promote tumour development and growth directly, or indirectly via prostaglandins; hence, the relationship between cytokines and advanced cancers is associated with an increased

risk of cancer mortality.<sup>100,129–131</sup> Particular attention has to be paid to the activity and downstream effects of prostaglandins. Prostaglandins are biologically active lipids generated from arachidonic acid via the enzyme cyclo-oxidase (COX). The COX-1 enzymes are present within normal tissues and are up-regulated in response to trauma, infection or chemical injury, generating an increase in prostaglandins triggering an appropriate inflammatory cascade and immune response. COX-2 is also increased by several cytokine and growth factor sub-families, with COX-2 known to be highly expressed in many tumours.<sup>132</sup> Chronic inappropriate and excessive production of prostaglandins, such as prostaglandin-2 (PGE<sub>2</sub>), have been implicated in cancer progression, apoptosis, invasion, angiogenesis and metastases.<sup>133,134</sup>

As well as anti-inflammatory drugs and fresh vegetables, regular non-traumatic exercise has been shown to reduce COX-2-mediated activation of prostaglandins, which could explain the reported anti-cancer properties of exercise.<sup>135–140</sup> For example, a study involving biopsies of rectal mucosa showed that leisure-time physical activity, particularly in overweight individuals, was associated with a 28% decline in prostaglandin E2 (PGE<sub>2</sub>).<sup>141</sup>

A state of chronic inflammation is more common among individuals with poor gut health which, via reduced gut wall integrity, allows more inflammatory toxins to pass into the body.<sup>142</sup> Poorer gut health is more likely in overweight sedentary individuals, malnourishment, type II diabetes and the elderly.<sup>125,127</sup> On the other hand, recent studies suggest that exercise can enhance the number of beneficial microbial species and enrich the microflora diversity, although its cause and effect has not been established.<sup>142–144</sup>

### *Muscle as an endocrine organ*

It is now well established that the muscular system is the largest endocrine organ in the body producing a range of hormones and cytokines signalling all other tissues, organs and systems.<sup>145</sup> During activation of muscle, as occurs in exercise, a range of molecules

are released many of which have been demonstrated to have cancer suppressive effects directly and by facilitating the release of immune cells, their activity and surveillance ability.<sup>146</sup> This may in part explain why patients with cancer that have low muscle mass experience greater disease and treatment issues and have compromised survival. Resistance training and other exercises are best strategy available to maintain or increase muscle mass and are recommended in most national statements on exercise for cancer care.<sup>147</sup> The larger the muscle mass of the patient, the greater production of anti-cancer molecules, and this muscle mass should be activated frequently, preferably daily at an intensity sufficient to dose the cancer with this ‘exercise medicine’.

### **Exercise, quality of life and toxicity**

Adverse cancer-related symptoms, which have been shown to be alleviated by exercise, include fatigue, muscle weakness, thromboembolism, weight gain, loss of bone density, quality of life (QOL), psychological distress, incontinence and sexual dysfunction.<sup>49</sup>

### **Physical activity improves well-being after cancer**

Through a combination of earlier detection and enhanced multidisciplinary management, the chances of surviving cancer are significantly improving year by year. Unfortunately, many of these individuals suffer from both acute and long-term physical and psychological adverse effects. These ongoing adverse toxicities affect their personal QOL as well as impacting substantially on their families, and their ability to regain fiscal autonomy. The adverse effects of cancer often result in the need for more frequent and costly medical interventions to manage chronic conditions including arthritis, depression, heart disease and diabetes. Fortunately, a physically active lifestyle and, particularly, supervised exercise rehabilitation programmes after cancer are linked to an improvement in many common adverse effects across multiple types of cancer. This has been



exhibited in patients receiving surgery, radiotherapy, chemotherapy, hormonal and biological therapies for cancer.<sup>148,150–153</sup>

### *Cancer-related fatigue*

Cancer-related fatigue (CRF) is one of the most disturbing symptoms experienced by men and women during and after anti-cancer management. It is reported in up to 90% of patients during chemotherapy, radiotherapy or after surgery, and nearly 40% of patients taking hormone or biological therapies.<sup>154</sup> Exercise interventions modestly improve CRF as revealed in a review 28 RCTs involving participants undertaking a range of exercise programmes.<sup>155</sup> This was confirmed in a further meta-analysis of 18 RCTs which also sub-divided the participants into home-based exercise programmes and supervised exercise programmes, which included a combination of aerobic and resistance exercises.<sup>166</sup> In this study, a statistically significant benefit of exercise for CRF was observed in breast cancer patients involved in supervised exercise programmes but not home-based programmes.

### *Anxiety, low mood and depression*

Anxiety, low mood and depression are reported in 25–30% of patients after cancer.<sup>156</sup> Exercise, especially if combined with relaxation, helps to elevate mood and self-esteem, enhance compliance to medical interventions, reduce depression and anxiety and reduce fears of relapse.<sup>67,156–168</sup> In addition, light exposure, which increases with outdoor exercise, has been linked to a reduction in non-seasonal depressive disorders.<sup>163</sup> As well as being emotionally distressing, individuals suffering from the psychological consequences of cancer have a lower survival in comparison to those free of psychological distress.<sup>162–167</sup> Of note, a large prospective cohort study from California reported that 4.6% of 41 000 men who were clinically depressed after prostate cancer had a 25% reduction in disease-specific survival compared with non-depressed men.<sup>167</sup> Another trial involving individuals from Korea with head and neck

cancer reported similar findings.<sup>168</sup> The mechanism by which exercise helps fight depression has not yet been firmly established but hypotheses include increased endorphin and monoamine release, mental distraction and rises in core body temperature.<sup>163</sup>

### *Physical fitness and QOL*

In a study involving patients with colorectal cancer, patients undertaking at least 150 minutes of physical activity per week had an 18% higher QOL score than those who reported no physical activity.<sup>168</sup> Another study showed similar benefits for breast cancer survivors who had completed surgery, radiotherapy or chemotherapy, and also demonstrated that change in peak oxygen consumption correlated with change in overall QOL.<sup>160</sup> A meta-analysis of 34 randomized trials published in the BMJ involving patients who undertook exercise after cancer showed improvements in muscle power, hand grip and exercise capacity as well as an enhanced mood and greater QOL, with reduced fatigue, anxiety and depression.<sup>149</sup> Other large meta-analyses from the USA and Australia have confirmed similar benefits.<sup>32,169</sup>

### *Arthritis*

Arthritis affects 55% of cancer survivors, impacting mobility and increasing the requirement for anti-inflammatory medication, which can result in cardiac and renal damage.<sup>178</sup> Several factors conspire to accelerate the natural tendency for humans to develop joint pains. These include surgery, chemotherapy and biological therapies, in particular hormonal treatments such as aromatase inhibitors (AI's). Not only is the swelling, pain and stiffness associated with arthritis troublesome, it can also affect compliance, potentially compromising the effectiveness of adjuvant therapies.<sup>170,171</sup> Furthermore, the symptoms of arthralgia can indirectly exacerbate other complications of cancer by restricting an individual's ability to mobilize freely. These complications include osteoporosis, hot flushes, weight gain and indeed a greater risk of cancer

relapse. In the general population, people who exercise have a lower incidence of arthritis. In addition, the landmark HOPE study from New York reported significantly enhanced joint function in breast cancer patients randomized to a supervised exercise and stretching programme when taking AI's.<sup>173</sup>

### *Bone mineral density loss*

Bone mineral density (BMD) loss is a prominent concern among both male and female cancer survivors. Premenopausal women following breast cancer are at increased risk because of reduced levels of oestrogen triggered by premature menopause due to chemotherapy, surgery or hormonal therapy. Men taking hormone deprivation therapy for CaP are also at an increased risk for developing osteoporosis.<sup>172,173</sup> Lifestyle factors linked to an increased risk of developing osteoporosis include a low calcium and vitamin D intake, a diet low in plant-based protein, lack of physical activity, smoking and excessive alcohol intake.<sup>175</sup> A number of studies have linked regular physical activity with an ameliorated risk of bone mineral loss.<sup>172,173</sup> An RCT involving women with breast cancer were randomized to standard care or an exercise intervention of either resistance exercise (with bands) or aerobic exercise (jogging or fast walking).<sup>172</sup> In this study, the rate of decline in BMD was significantly less in the resistance exercise group, with a greater benefit seen in the aerobic exercise group particularly among premenopausal women.<sup>172</sup> Declining bone density is particularly problematic in men on androgen deprivation therapy for their prostate cancer with one RCT demonstrating resistance training to be ineffective; however, the combination of resistance training and impact exercise (skipping, hopping, bounding) completely nullified the bone loss.<sup>172</sup>

### *Thromboembolism*

Thromboembolism remains a significant risk for patients with malignancy, particularly those with pelvic involvement, those who underwent recent

surgery and/or chemotherapy or those who have a history of immobility, varicose veins or thromboses.<sup>174</sup> Although strategies such as compression stockings, warfarin and low molecular weight heparin are essential, early mobilization and exercise remains an important practical aid in reducing this life-threatening complication.<sup>50,153</sup>

### *Other conditions improved with exercise*

Constipation caused by immobility, opiate analgesics or anti-emetics during chemotherapy is a significant patient concern. Exercise reduces bowel transit time and ameliorates constipation and its associated abdominal cramps.<sup>155</sup> Exercise has been linked to lower cognitive impairment from chemotherapy (Chemo-brain) and hormonal therapies.<sup>49,147–150</sup>

## **Discussion and conclusions**

The importance of physical activity before, during and after cancer treatments is being appreciated as emerging evidence indicates that exercise improves several common side effects associated with cancer therapies and correlates with an improved overall survival and a lower probability of relapse. The most feasible biochemical pathways, supporting a direct and indirect anticancer mechanism of action, have been summarized in this article, but there are likely to be others which remain undiscovered. Furthermore, it remains unclear which of these mechanisms plays the most important role, whether they are person or disease-dependent and whether they could be enhanced by diet and other lifestyle modifications.

It also appears that it is never too late to start exercising with cancer. The clinical value of physical fitness prior to surgery is well established. Physically fit surgical candidates have lower peri-operative complication rates and quicker recoveries compared with their less-fit counterparts.<sup>180–183</sup> It is likely that prehabilitation may also help mitigate an increase in COVID-19 surgical morbidity and mortality.<sup>177</sup> Beyond surgery, better physical function, muscle volume and exercise levels have been connected to higher rates of response and enhanced tolerance

to chemotherapy, hormone therapies, radiotherapy and even the newer targeted immunotherapies.<sup>7,176–180</sup> There is growing interest in exercise during chemotherapy administration as a way to alter blood flow and tumour microenvironment making cancer cells more susceptible to treatments, although more clinical research is required before exercise bikes are routinely implemented into chemotherapy units.

Dozens of interventional studies have tested the feasibility and potential benefits of exercise in cancer survivors.<sup>33,34,37</sup> Despite the benefits, implementation of formal prehabilitation and rehabilitation programmes for patients with cancer across the UK tends to be sporadic and exercise levels after cancer remain low.<sup>180</sup> The exception is private hospital groups such as Genesis Care, which have routine exercise medicine facilities in most of their chemotherapy and radiotherapy centres.<sup>182</sup> Wider funding for a national exercise programme has been hampered by the shortage of RCT's and cost effectiveness research. Macmillan Cancer Care is collaborating with the Royal College of Anaesthetist and National Institute of Health research (NIHR) to develop these principles and guidance together with an action plan.<sup>182</sup> This sets out how NHS organizations across the UK can replicate some of the pioneering work already taking place at a limited number of Trusts. In particular, it is developing formal guidance for patient identification and prioritization for a prehabilitation and collaborative, inter-professional program exercise prescription considerations and parameters, and effectiveness monitoring and follow-up. In the meantime, the results of several large randomized clinical trials are eagerly awaited, which are evaluating the potential magnitude of the effect which physical activity and/or exercise interventions have on cancer patients and survivors (188). These include the [BreastCancerWeightLoss\(BWEL\)trial](#) in newly diagnosed breast cancer patients, the CHALLENGE trial in colon cancer patients who have recently completed chemotherapy and the INTERVAL-GAP4 trial in men with metastatic, hormone-sensitive or [castrate-resistantprostatecancer](#).<sup>159,183</sup>

## Data availability statement

No new data were generated or analysed in support of this review.

## Acknowledgements

Professor Kenfield is funded from the National Cancer Institute (R01CA207749) and the Helen Diller Family Chair in Population Science for Urologic Cancer.

## References

1. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. *J Clin Oncol* 2011;29:726–32. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056656/>.
2. Dieli-Conwright CM, Ma H, Lacey JV Jr et al. Long-term and baseline recreational physical activity and risk of endometrial cancer: the California teachers study. *Br J Cancer* 2013;109:761–8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738142/>.
3. Liu L, Shi Y, Qin Q et al. Leisure time physical activity and cancer risk: evaluation of the WHO's recommendation based on 126 high-quality epidemiological studies. *Br J Sports Med* 2016;50:372–8. <https://bjsm.bmj.com/content/50/6/372.long>.
4. Giovannucci EL, Liu Y, Leitzmann MF et al. A prospective study of physical activity and incident and fatal prostate cancer. *JAMA* 2005;165:1005–10. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1152790>.
5. Girdl GG. The Melbourne collaborative cohort study. *IARC Sci Publ* 2002;156:69–70.
6. McTiernan A, Friedenreich CM, Katzmarzyk PT et al. Physical activity in cancer prevention and survival: a systematic review. *Med Sci Sports Exerc* 2019;51:1252–61. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527123/>.
7. Irwin ML, Smith AW, McTiernan A et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. *J Clin Oncol* 2008;26:3958–64. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654316/>.
8. Friedenreich C, Cust A, Lahmann PH et al. Physical activity and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. *Int J Cancer* 2007;121:347–55. <https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.22676>.

9. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. *J Nutr* 2002;132:3456–64. <https://academic.oup.com/jn/article/132/11/3456/4687180>.
10. Machado de Rezende LF, Herick de Sa T, Markozannes G et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. *Br J Sports Med* 2018;52:826–33. <https://bjsm.bmj.com/content/52/13/826.long>.
11. Richman EL, Kenfield SA, Stampfer MJ et al. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavour. *Cancer Res* 2011;71:3889–95. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107352/>.
12. Spencer EA, Appleby PN, Davey GK, Key TJ. Diet and body mass index in 38000 EPIC-Oxford meat-eaters, fish-eaters, vegetarians and vegans. *Int J Obes* 2003;27:728–34. <https://www.nature.com/articles/0802300>.
13. Patel AV, Hildebrand JS, Campbell PT et al. Leisure-time spent sitting and site-specific cancer incidence in a large U.S. cohort. *Cancer Epidemiol Biomark Prev* 2015;24:1350–9. <https://cebp.aacrjournals.org/content/24/9/1350.long>.
14. Patel AV, Friedenreich CM, Moore SC et al. American College of Sports Medicine roundtable report on physical activity, sedentary behaviour, and cancer prevention and control. *Med Sci Sports Exerc* 2019;51:2391–402. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814265/>.
15. Campbell KL, Winters-Stone KM, Wiskemann J et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. *Med Sci Sports Exerc* 2019;51:2375–90. [https://journals.lww.com/acsm-msse/Fulltext/2019/11000/Exercise\\_Guidelines\\_for\\_Cancer\\_Survivors\\_23.aspx](https://journals.lww.com/acsm-msse/Fulltext/2019/11000/Exercise_Guidelines_for_Cancer_Survivors_23.aspx).
16. Office of Disease Prevention and Health Promotion. U.S. Department of Health and Human Service. *Physical Activity Guidelines Advisory Committee Scientific Report*.
17. Pizot C, Boniol M, Mullie P et al. Physical activity, hormone replacement therapy and breast cancer risk: a meta-analysis of prospective studies. *Eur J Cancer* 2016;52:138–54. <https://strathprints.strath.ac.uk/55321/>.
18. Hardefeldt PJ, Penninkilampi R, Edirimanne S, Eslick GD. Physical activity and weight loss reduce the risk of breast cancer: a meta-analysis of 139 prospective and retrospective studies. *Clin Breast Cancer* 2018;18:601–12. [https://www.clinical-breast-cancer.com/article/S1526-8209\(16\)30429-3/fulltext](https://www.clinical-breast-cancer.com/article/S1526-8209(16)30429-3/fulltext).
19. Eliassen AH, Hankinson SE, Rosner B et al. Physical activity and risk of breast cancer among postmenopausal women. *Arch Intern Med* 2011;170:1758–64. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142573/>.
20. Fournier A, Dos Santos G, Guillas G et al. Recent recreational physical activity and breast cancer risk in postmenopausal women in the E3N cohort. *Cancer Epidemiol Biomark Prev* 2014;23:1893–902. <https://cebp.aacrjournals.org/content/23/9/1893.long>.
21. Moore SC, Lee IM, Weiderpass E et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med* 2016;176:816–25. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2521826>.
22. Keimling M, Behrens G, Schmid D et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. *Br J Cancer* 2014;110:1862–70. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974090/>.
23. Schmid D, Behrens G, Keimling M et al. A systematic review and meta-analysis of physical activity and endometrial cancer risk. *Eur J Epidemiol* 2015;30:397–412. <https://link.springer.com/article/10.1007/s10654-015-0017-6>.
24. Du M, Kraft P, Eliassen AH et al. Physical activity and risk of endometrial adenocarcinoma in the nurses' health study. *Int J Cancer* 2014;134:2707–16. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960316/>.
25. Borch KB, Weiderpass E, Braaten T et al. Physical activity and risk of endometrial cancer in the Norwegian Women and Cancer (NOWAC) Study. *Int J Cancer* 2017;140:1809–18. <https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.30610>.
26. Behrens G, Jochem C, Keimling M et al. The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis. *Eur J Epidemiol* 2014;29:151–70. <https://link.springer.com/article/10.1007%2Fs10654-014-9895-2>.
27. Psaltopoulou T, Ntanasis-Stathopoulos I, Tzanninis IG et al. Physical activity and gastric cancer risk: a systematic review and meta-analysis. *Clin J Sport Med* 2016;26:445–64. <https://pubmed.ncbi.nlm.nih.gov/27347864/>.
28. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review

- and meta-analysis. *Br J Cancer* 2013;108:798–811. <https://www.nature.com/articles/bjc201337>.
29. Pierce JP, Stefanick ML, Flatt SW et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. *J Clin Oncol* 2007;25:2345–51. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2274898/>.
  30. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. *N Engl J Med* 1997;336:1269–75. <https://www.nejm.org/doi/10.1056/NEJM199705013361801>.
  31. Biswas A, Oh PI, Faulkner GE et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. *Ann Intern Med* 2015;162:123–32. <https://www.acpjournals.org/doi/10.7326/M14-1651>.
  32. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. *Ann Oncol* 2014;25:1293–311. [https://linkinghub.elsevier.com/retrieve/pii/S0923-7534\(19\)36684-0](https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(19)36684-0).
  33. Schmitz KH, Courneya KS, Matthews C et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc* 2010;42:1409–26. [https://journals.lww.com/acsm-msse/Fulltext/2010/07000/American\\_College\\_of\\_Sports\\_Medicine\\_Roundtable\\_on.23.aspx](https://journals.lww.com/acsm-msse/Fulltext/2010/07000/American_College_of_Sports_Medicine_Roundtable_on.23.aspx).
  34. Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. *Cochrane Database Syst Rev* 2016;9:CD005001. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457768/>.
  35. Chelbowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *J Clin Oncol* 2002;20:1128–43. <https://ascopubs.org/doi/10.1200/JCO.2002.20.4.1128>.
  36. Haydon AMM, Mac Innis RJ, English DR, Giles GG. The effect of physical activity and body size on survival after diagnosis with colorectal cancer. *Gut* 2006;55:62–7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856365/>.
  37. McNeely ML, Campbell KL, Rowe BH et al. Effects of exercise on breast cancer patients and survivors: a systemic review and meta-analysis. *Can Med Assoc J* 2006;175:34–41. <https://www.cmaj.ca/content/175/1/34.long>.
  38. Holmes MD, Chen WY, Feskanich D et al. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005;293:2479–86. <https://jamanetwork.com/journals/jama/fullarticle/200955>.
  39. Holick CN, Newcomb PA, Trentham-Dietz A et al. Physical activity and survival after diagnosis of invasive breast cancer. *Cancer Epidemiol Biomark Prev* 2008;17:379–86. <https://cebp.aacrjournals.org/content/17/2/379.long>.
  40. Sternfeld B, Weltzien E, Charles P et al. Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. *Cancer Epidemiol Biomark Prev* 2009;18:87–95. <https://cebp.aacrjournals.org/content/18/1/87.long>.
  41. Chen X, Lu W, Zheng W et al. Exercise after diagnosis of breast cancer in association with survival. *Cancer Prev Res* 2011;4:1409–18. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169008>.
  42. Spei ME, Samoli E, Bravi F. et al. Physical activity in breast cancer survivors: a systematic review and meta-analysis on overall and breast cancer survival. *Breast* 2019;44:144–52. [https://www.thebreastonline.com/article/S0960-9776\(19\)30020-7/fulltext](https://www.thebreastonline.com/article/S0960-9776(19)30020-7/fulltext).
  43. Meyerhardt JA, Giovannucci EL, Ogino S et al. Physical activity and male colorectal cancer survival. *Arch Intern Med* 2009;169:2102–8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852183>.
  44. Haydon AM, McInnis RJ, English DR et al. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. *Gut* 2006;55:689–94. <https://gut.bmj.com/content/55/5/689>.
  45. Meyerhardt JA, Heseltine D, Niedzwiecki D et al. The impact of physical activity on patients with stage III colon cancer: findings from intergroup trial CALGB 89803. *J Clin Oncol* 2005;23:3535–341. [https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16\\_suppl.3534](https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.3534).
  46. Ballard-Barbash R, Friedenreich CM, Courneya KS et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. *J Natl Cancer Inst* 2012;104:815–40. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465697/>.
  47. Ornish D, Weidner G, Fair WR et al. Intensive lifestyle changes may affect the progression of prostate cancer. *J Urol* 2005;174:1065–70. <https://www.auajournals.org/doi/10.1097/01.ju.0000169487.49018.73>.
  48. Ploeger HE, Takken T, de Greef MH, Timmons BW. The effects of acute and chronic exercise on inflammatory markers in children and adults with chronic inflammatory disease: a systemic review. *Exerc*

- Immunol Rev* 2009;15:6–41. <http://eir-isei.de/2009/eir-2009-006-article.pdf>.
49. Thomas R, Holm M, Bellamy P *et al.* Lifestyle factors correlate with the risk of late pelvic symptoms after prostatic radiotherapy. *Clin Oncol (R Coll Radiol)* 2013;25:246–51. [https://www.clinicaloncologyonline.net/article/S0936-6555\(12\)00361-5/fulltext](https://www.clinicaloncologyonline.net/article/S0936-6555(12)00361-5/fulltext).
  50. Knols R, Aaronson NK, Uebelhart D *et al.* Physical exercise in cancer patients during and after medical treatment: a systemic review of randomized controlled trials. *J Clin Oncol* 2005;23:3830–42. <https://ascopubs.org/doi/10.1200/JCO.2005.02.148>.
  51. Surmacz E. Obesity hormone leptin; a new target for breast cancer? *Breast Cancer Res* 2007;9:301. <https://breast-cancer-research.biomedcentral.com/articles/10.1186>.
  52. Hoffmann-Goetz L, Apter D, Demark-Wahnefried W *et al.* Possible mechanisms mediating an association between physical activity and breast cancer. *Cancer* 1998;83:621–8. <https://pubmed.ncbi.nlm.nih.gov/9690525/>.
  53. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. *Obes Rev* 2015;16:473–87. <https://onlinelibrary.wiley.com/doi/10.1111/obr.12281>.
  54. Kaaks R, Lukanova A. Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. *Ann N Y Acad Sci* 2002;963:268–81. <https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111>.
  55. Irwin ML, Varma K, Alvarez-Reeves M *et al.* Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale exercise and survivorship study. *Cancer Epidemiol Biomark Prev* 2009;18:306–13. <https://cebp.aacrjournals.org/content/18/1/306.long>.
  56. Wu AH, Yu MC. Tea, hormone-related cancers and endogenous hormone levels. *Mol Nutr Food Res* 2006;50:160–9. <https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.200500142>.
  57. Folkert EJ, Mitch D. Influence of sex hormones on cancer progression. *J Clin Oncol* 2010;28:4034–44. <https://ascopubs.org/doi/10.1200/JCO.2009.27.4290>.
  58. Niu J, Jiang L, Guo W *et al.* The association between leptin level and breast Cancer: a meta-analysis. *PLoS One* 2013;8:e67349. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0067349>.
  59. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Hormone molecular biology and clinical investigation. *Horm Mol Biol Clin Invest* 2015;21:57–74. <https://www.degruyter.com/document/doi/10.1515/hmbci-2014-0037/html>.
  60. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. *J Korean Med Sci* 2007;22:117–21. <https://jkms.org/DOIx.php?id=10.3346/jkms.2007.22.1.117>.
  61. Rock CL, Flatt SW, Byers TE *et al.* Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: a behavioural weight loss intervention in overweight or obese breast cancer survivors. *J Clin Oncol* 2015;33:3169–76. <https://ascopubs.org/doi/10.1200/JCO.2015.61.1095>.
  62. Foster-Schubert K, Alfano C, Duggan C *et al.* Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese post-menopausal women. *Obesity* 2012;20:1628–38. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406229/>.
  63. Abbenhardt C, McTiernan A, Alfano CM *et al.* Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels. *J Intern Med* 2013;274:163–75. <https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12062>.
  64. Lin X, Zhang X, Guo J *et al.* Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2015;4:e002014. <https://www.ahajournals.org/doi/10.1161/JAHA.115.002014>.
  65. Friedenreich CM, Woolcott CG, McTiernan A *et al.* Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. *J Clin Oncol* 2010;28:1458–66. <https://ascopubs.org/doi/10.1200/JCO.2009.24.9557>.
  66. Kossman D, Williams N, Domcheck S *et al.* Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer. *J Appl Physiol* 2011;111:1687–93. <https://journals.physiology.org/doi/full/10.1152/>.
  67. Kraemer RR. Leptin levels reduce after exercise. *Exp Biol Med* 2002;227:701–8.
  68. Schmitz KH, Williams NI, Kontos D *et al.* Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. *Breast Cancer Res*

- Treat* 2015;154:309–18. <https://link.springer.com/article/10.1007%2Fs10549-015-3604-z>.
69. Hackney AC. Endurance exercise training and reproductive endocrine dysfunction in men: alterations in the hypothalamic-pituitary-testicular axis. *Curr Pharm Des* 2001;7:261–73. <https://pubmed.ncbi.nlm.nih.gov/11254889/>.
  70. Sgro P, Romanelli F, Felici D et al. Testosterone responses to standardized short-term sub-maximal and maximal endurance exercises: issues on the dynamic adaptive role of the hypothalamic-pituitary-testicular axis. *J Endocrinol Investig* 2014;37:13–24. <https://link.springer.com/article/10.1007/s40618-013-0006-0>.
  71. Enea C, Boisseau N, Ottavy M et al. Effects of menstrual cycle, oral contraception, and training on exercise-induced changes in circulating DHEA-sulphate and testosterone in young women. *Eur J Appl Physiol* 2009;106:365–73. <https://link.springer.com/article/10.1007%2Fs00421-009-1017-6>.
  72. Niklas BJ, Ryan AJ, Treuth MM et al. Testosterone, growth hormone and IGF-I responses to acute and chronic resistive exercise in men aged 55-70 yrs. *Int J Sports Med* 1995;16:445–50. <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-973035>.
  73. Craig BW, Brown R, Everhart J. Effects of progressive resistance training on growth hormone and testosterone levels in young and elderly subjects. *Mech Ageing Dev* 1989;49:159–69. <https://www.sciencedirect.com/science/article/abs/pii/0047637489900997?via%3Dihub>.
  74. Jensen J, Oftebro H, Breigan B et al. Comparison of changes in testosterone concentrations after strength and endurance exercise in well trained men. *Eur J Appl Physiol Occup Physiol* 1991;63:467–71.
  75. Sutton JR, Coleman MJ, Casey J, Lazarus L. Androgen response during physical exercise. *Br Med J* 1973;1:520–2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1588661/>.
  76. Hayes LD. Six weeks of conditioning exercise increases total, but not free testosterone in lifelong sedentary aging men. *Aging Male* 2015;18:195–200. <https://www.tandfonline.com/doi/abs/10.3109/13685538>.
  77. Mac Kelvie KJ, Taunton JE, McKay HA, Khan KM. Bone mineral density and serum testosterone in chronically trained, high mileage 40–55-year-old male runners. *Br J Sports Med* 2000;34:273–8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1724199/>.
  78. Hawkins VN, Foster-Schubert K, Chubak J et al. Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. *Med Sci Sports Exerc* 2008;40:223–33. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040039/>.
  79. Safarinejad MR, Azma K, Kolahi AA. The effects of intensive, long-term treadmill running on reproductive hormones, hypothalamus-pituitary-testis axis, and semen quality: a randomized controlled study. *J Endocrinol* 2009;200:259–71. <https://joe.bioscientifica.com/view/journals/joe/200/3/259.xml>.
  80. Haring R, Ittermann T, Voelzke H et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health Pomerania. *Aging Male* 2010;13:247–57.
  81. Wallis CJD, Yonah K, Antonio F. Low testosterone and prostate cancer: is the protection real? *Eur Urol* 2018;74:595–6. <https://www.sciencedirect.com/science/article/abs/pii/S030228381830616X>.
  82. Chomistek AK, Chiuvè SE, Jensen MK et al. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. *Med Sci Sports Exerc* 2011;43:1884–90. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249756/>.
  83. Schottker B, Haug U, Schomburg L et al. Strong associations of 25-hydroxyvitamin D concentrations with all- cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. *Am J Clin Nutr* 2013;97:782–93. <https://academic.oup.com/ajcn/article/97/4/782/4577069>.
  84. Lazzeroni M, Serrano D, Pilz S, Gandini S. Vitamin d supplementation and cancer: a review of randomized controlled trials. *Anti Cancer Agents Med Chem* 2013;13:118–25. <https://www.eurekaselect.com/105344/article>.
  85. Schwartz GG. Vitamin D, sunlight, and the epidemiology of prostate cancer. *Anti Cancer Agents Med Chem* 2013;13:45–57. <https://www.eurekaselect.com/105337/article>.
  86. Chiang KC, Chen TC. The anti-cancer actions of vitamin D. *Anti Cancer Agents Med Chem* 2013;13:126–39. <https://www.eurekaselect.com/105382/article>.
  87. Zgaga L, Theodoratou E, Farrington S et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. *J Clin Oncol* 2014;32:2430–9. <https://ascopubs.org/doi/10.1200/JCO.2013.54.5947>.
  88. Ng K, Meyerhardt J, Wu K et al. Circulating 25-Hydroxyvitamin D levels and survival in patients with colorectal Cancer. *J Clin Oncol* 2008;26:

- 2984–91. <https://ascopubs.org/doi/10.1200/JCO.2007.15.1027>.
89. Pilz S, Kienreich K, Tomaschitz A et al. Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. *Anti Cancer Agents Med Chem* 2013;13:107–17. <https://www.eurekaselect.com/105343/article>.
  90. Giovannucci E. Epidemiology of vitamin D and colorectal cancer. *Anti Cancer Agents Med Chem* 2013; 13:11–9. <https://www.eurekaselect.com/105334/article>.
  91. Rose AA, Elser C, Ennis M, Goodwin PJ. Blood levels of vitamin D and early-stage breast cancer prognosis: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2013;143:331–9. <https://link.springer.com/article/10.1007/s10549-013-2713-9>.
  92. Luscombe C, French M, Liu S et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. *Br J Cancer* 2001;85:1504–9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363930/>.
  93. Van der Rhee H, Coebergh JW, de Vries E. Is prevention of cancer by sun exposure more than just the effect of vitamin D? A systematic review of epidemiological studies. *Eur J Cancer* 2013;49:1422–36. [https://linkinghub.elsevier.com/retrieve/pii/S0959-8049\(12\)00885-4](https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(12)00885-4).
  94. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. *J Natl Cancer Inst* 2000;92:1472–89. <https://academic.oup.com/jnci/article/92/18/1472/2909573>.
  95. Lubik AA, Gunter JH, Hollier BG et al. IGF2 increases de novo steroidogenesis in prostate cancer cells. *Endocr Relat Cancer* 2013;20:173–86. <https://erc.bioscientifica.com/view/journals/erc/20/2/173.xml>.
  96. Palmqvist R, Halmans G, Rinaldi S et al. Plasma insulin-like growth factor, insulin-like growth factor binding protein, and colorectal cancer: a prospective study in northern Sweden. *Gut* 2002;50:642–6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773192/>.
  97. Ma J, Pollak M, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin like growth factor (IGF)-1 and IGF binding protein-3. *J Natl Cancer Inst* 1999;91:620–5. <https://academic.oup.com/jnci/article/91/7/620/2543977>.
  98. Segal R, Reid RD, Courneya KS et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. *J Clin Oncol* 2009;20:344–51. <https://ascopubs.org/doi/10.1200/JCO.2007.15.4963>.
  99. Hvid T, Winding K, Rinnov A et al. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. *Endocr Relat Cancer* 2013;20:621–32. <https://erc.bioscientifica.com/view/journals/erc/20/5/621.xml>.
  100. Cormie P, Galvão DA, Spry N et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. *BJU Int* 2015;115:256–66. <https://doi.org/10.1111/bju.12646>. Epub 2014 Jul 27 PMID: 24467669.
  101. Larsson S, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. *Int J Cancer* 2007;121:856–62. <https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.22717>.
  102. Flanagan J, Gray PK, Hahn N et al. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. *Ann Oncol* 2011;22:801–7. [https://linkinghub.elsevier.com/retrieve/pii/S0923-7534\(19\)38552-7](https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(19)38552-7).
  103. Ma J, Li H, Giovannucci E et al. Pre-diagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol* 2008;9:1039–47. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651222/>.
  104. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the classical, resistin—the controversial, adiponectin—the promising, and more to come. *Best Pract Res Clin Endocrinol Metab* 2005;19:526–46. <https://www.sciencedirect.com/science/article/abs/pii/S1521690X05000515>.
  105. Zimmerlin L, Donnenberg A, Rubin A et al. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. *Tissue Eng* 2011;17:93–106. <https://www.liebertpub.com/doi/10.1089/ten.TEA.2010.0248>.
  106. Rhee H, Gunter JH, Heathcote P et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. *BJU Int* 2015;115: 3–13. <https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.12964>.
  107. Ornish D, Magbanua MJ, Weider G et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. *Proc Natl Acad Sci U S A* 2008;105:8369–74. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430265/>.



108. Magbanua MJ, Richman EL, Sosa EV et al. Physical activity and prostate gene expression in men with low-risk prostate cancer. *Cancer Causes Control* 2014;25:515–23. <http://link.springer.com/article/10.1007%2Fs10552-014-0354-x>.
109. Wang M, Yu B, Westerlind K et al. Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland. *Breast Cancer Res Treat* 2009;115: 213–20. <https://link.springer.com/article/10.1007%2Fs10549-008-0062-x>.
110. Pijpe A, Manders P, Brohet RM et al. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. *Breast Cancer Res Treat* 2010;120: 235–44. <https://link.springer.com/article/10.1007%2Fs10549-009-0476-0>.
111. Sharafi H, Rahimi R. The effect of resistance exercise on p53, Caspase-9, and Caspase-3 in trained and untrained men. *J Strength Cond Res* 2012;26:1142–8. [https://journals.lww.com/nsca-jscr/Fulltext/2012/04000/The\\_Effect\\_of\\_Resistance\\_Exercise\\_on\\_p53,.34.aspx](https://journals.lww.com/nsca-jscr/Fulltext/2012/04000/The_Effect_of_Resistance_Exercise_on_p53,.34.aspx).
112. Ornish D, Lin J, Chan JM et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. *Lancet Oncol* 2013;14:1112–20. [https://linkinghub.elsevier.com/retrieve/pii/S1470-2045\(13\)70366-8](https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(13)70366-8).
113. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. *Eur J Cancer Prev* 2012;21:155–62. [https://journals.lww.com/eurjancerprev/Abstract/2012/03000/The\\_role\\_of\\_oxidative\\_stress\\_in\\_prostate\\_cancer.7.aspx](https://journals.lww.com/eurjancerprev/Abstract/2012/03000/The_role_of_oxidative_stress_in_prostate_cancer.7.aspx).
114. Niess AM, Dickhuth HH, Northoff H, Fehrenbach E. Free radicals and oxidative stress in exercise-immunological aspects. *Exerc Immunol Rev* 1999;5: 22–56. <https://pubmed.ncbi.nlm.nih.gov/10519061/>.
115. Fehrenbach E, Northoff H. Free radicals, exercise, apoptosis, and heat shock proteins. *Exerc Immunol Rev* 2001;7:66–89. <https://pubmed.ncbi.nlm.nih.gov/11579749/>.
116. Mackinnon IT. Current challenges and future expectations in exercise immunology: back to the future. *Med Sci Sports Exerc* 1994;26:191–4. [https://journals.lww.com/acsm-msse/Abstract/1994/02000/Current\\_challenges\\_and\\_future\\_expectations\\_in.9.aspx](https://journals.lww.com/acsm-msse/Abstract/1994/02000/Current_challenges_and_future_expectations_in.9.aspx).
117. Gomez-Cabrera MC, Martinez A, Santangelo G et al. Oxidative stress in marathon runners: interest of antioxidant supplementation. *Br J Nutr* 2006;96:31–3. <https://pubmed.ncbi.nlm.nih.gov/16923247/>.
118. Gomez-Cabrera MC, Domenech E, Vina J. Moderate exercise is an antioxidant: up regulation of antioxidant genes by training. *Free Radic Biol Med* 2008;44:126–31. <https://www.sciencedirect.com/science/article/abs/pii/S0891584907001086>.
119. Ji LL. Exercise at old age: does it increase or alleviate oxidative stress? *Ann N Y Acad Sci* 2001;928:236–47. <https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.2001>.
120. Nicklas BJ, Hsu FC, Brinkley TJ et al. Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. *J Am Geriatr Soc* 2008;56:2045–52. <https://agsjournals.onlinelibrary.wiley.com/doi/abs/10.1111/j.1532-5415.2008.01994.x>.
121. Zimmer P, Jager E, Bloch W et al. Influence of a six-month endurance exercise program on the immune function of prostate cancer patients undergoing antiandrogen therapy or chemotherapy: design and rationale of the ProImmune study. *BMC Cancer* 2013;13:272–277. <https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-272>.
122. Matthews CE, Ockene IS, Freedson PS et al. Moderate to vigorous physical activity and the risk of upper-respiratory tract infection. *Med Sci Sports Exerc* 2002;34:1242–8. [https://journals.lww.com/acsm-msse/Fulltext/2002/08000/Moderate\\_to\\_vigorous\\_physical\\_activity\\_and\\_risk\\_of.3.aspx](https://journals.lww.com/acsm-msse/Fulltext/2002/08000/Moderate_to_vigorous_physical_activity_and_risk_of.3.aspx).
123. Hoffman-Goetz L, Pedersen BK. Exercise and the immune system: a model of the stress response? *Immunol Today* 1994;15:382–7. <https://www.sciencedirect.com/science/article/abs/pii/0167569994901775>.
124. Rukavina D, Laskarin G, Rubesa G et al. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. *Blood* 1998;92:2410–20. <https://ashpublications.org/blood/article/92/7/2410/249082/>.
125. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. *Immunol Today* 1995;16:12–6. <https://www.sciencedirect.com/science/article/abs/pii/0167569995800646>.
126. Khanasari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. *Recent Patents Inflamm Allergy Drug Discov* 2009;3:73–80. <https://www.eurekaselect.com/930895/article>.

127. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006;444:860–7. <https://www.nature.com/articles/nature05485>.
128. Nijhuis J, Rensen SS, Slaats Y *et al.* Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity* 2009;17:2014–8. <https://online.library.wiley.com/doi/full/10.1038/oby.2009.113>.
129. Stark JR, Li H, Kraft P *et al.* Circulating pre-diagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. *Int J Cancer* 2009;124:2683–9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667697/>.
130. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-kappaB in prostate cancer lymph node metastases. *Prostate* 2004;68:308–13. <https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.10335>.
131. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. *Br J Cancer* 2004;90:2312–6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409519/>.
132. Madaan S, Abel PD, Chaudhary KS *et al.* Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. *Int J Oncol* 2000;86:736–41. <https://bjui-journals.onlinelibrary.wiley.com/doi/abs/10.1046/j.1464-410x.2000.00867>.
133. Hsu AL, Ching TT, Wang DS *et al.* The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J Biol Chem* 2000;275:113397–1403. [https://linkinghub.elsevier.com/retrieve/pii/S0021-9258\(19\)80994-8](https://linkinghub.elsevier.com/retrieve/pii/S0021-9258(19)80994-8).
134. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. *Cancer Res* 1998;58:4245–9. <https://cancerres.aacrjournals.org/content/58/19/4245.long>.
135. Greenberg ER, Baron JA, Freeman DH *et al.* Reduced risk of large-bowel adenomas among aspirin users. The polyp prevention study group. *J Natl Cancer Inst* 1993;85:912–6. <https://academic.oup.com/jnci/article-abstract/85/11/912/922036>.
136. Thun MJ, Nambodiri MM, Heath CWJR. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991;325:1593–6. <https://www.nejm.org/doi/10.1056/NEJM199112053252301>.
137. Harris RE, Namboodiri KK, Farrar WB. Non-steroidal anti-inflammatory drugs and breast cancer. *Epidemiology* 1996;7:203–5.
138. Anderson D, Pojer R, Smith I, Temple D. Exercise-related changes in plasma levels of 15-keto-13, 14-dihydro-prostaglandin F2alpha and noradrenaline in asthmatic and normal subjects. *Scand J Respir Dis* 1976;57:41–8. <https://pubmed.ncbi.nlm.nih.gov/1273543/>.
139. Blacklock CJ, Lawrence JR, Wiles D *et al.* Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. *J Clin Pathol* 2001;54:553–5. <https://jcp.bmj.com/content/54/7/553.long>.
140. Fairey AS, Courneya KS, Field CJ, Mackey JR. Physical activity and immune system function in cancer survivors. *Am Cancer Soc* 2001;94:539–51. <https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/>.
141. Martinez ME, Heddens D, Earnest DL *et al.* Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. *J Natl Cancer Inst* 1999;91:950–3. <https://academic.oup.com/jnci/article/91/11/950/2543683>.
142. Hakansson A, Molin G. Gut microbiota and inflammation. *Nutrients* 2011;3:637–82. <https://www.mdpi.com/2072-6643/3/6/637>.
143. Monda V, Villano I, Messina A *et al.* Exercise modifies the gut microbiota with positive health effects. *Oxidative Med Cell Longev* 2017;10:3831972. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357536/>.
144. Clarke S, Murphy EF, O'Sullivan O *et al.* Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* 2014;63:1913–20. <https://gut.bmj.com/content/63/12/1913.long>.
145. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. *Physiol Rev* 2008;88:1379–406.
146. Kim J, Galvão DA, Newton RU *et al.* Prostate cancer and myokines: potential effect of systemic alteration by exercise. *Nat Rev Urol* 2021;10:501–518. In Press.
147. Hayes SC, Newton RU, Spence RR, Galvão DA. The exercise and sports science Australia position statement: exercise medicine in cancer management. *J Sci Med Sport* 2019;22:1175–99.
148. Fong DYT, Ho JWT, Hui BPH *et al.* Physical activity for cancer survivors: meta-analysis of randomised controlled trials. *Br Med J* 2012;344:70–81. <https://www.bmj.com/content/344/bmj.e70.long>.
149. Thomas R, Williams M, Taylor T. Life after cancer – rehabilitation at home can improve well-being and survival. *Br J Home Healthcare* 2009;5:10–2.

150. Davis N, Bateman L, Thomas R. Exercise and lifestyle after cancer – evidence review. *Br J Cancer* 2011;105:52–73.
151. Gerritsen, Vincent JKW, AJPE. Exercise improves quality of life in patients with cancer: a systemic review and meta-analysis of randomized controlled trials. *Br J Sports Med* 2016;50:796–803. <https://bjsm.bmj.com/content/50/13/796.long>.
152. Schmitz KH, Campbell AM, Stuiver MM et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. *CA Cancer J Clin* 2019;69:468–84. <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21579>.
153. Thomas R, Kenfield SA, Jimenez A. The benefits of exercise after cancer – an international review of the clinical and microbiological benefits. *Br J Medical Pract* 2014;7:2–9.
154. Wagner LI. Fatigue and cancer: causes, prevalence and treatment approaches. *Br J Cancer* 2004;91:822–8. <https://www.nature.com/articles/6602012>.
155. Cramp F. Exercise for the management of cancer-related fatigue in adults. *Cochrane Database Syst Rev* 2008;16:CD006145. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006145.pub2/full>.
156. Drouin JS, Armstrong H, Krause S et al. Effects of aerobic exercise training on peak aerobic capacity, fatigue, and psychological factors during radiation for breast cancer. *Rehabil Oncol* 2005;23:11–7. [https://journals.lww.com/rehabonc/Citation/2005/23010/Effects\\_of\\_Aerobic\\_Exercise\\_Training\\_on\\_Peak.4.aspx](https://journals.lww.com/rehabonc/Citation/2005/23010/Effects_of_Aerobic_Exercise_Training_on_Peak.4.aspx).
157. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. *Prim Care Companion J Clin Psychiatry* 2004;6:104–11. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC474733/>.
158. Reid-Arndt SA, Cox CR. Stress, coping and cognitive deficits in women after surgery for breast cancer. *J Clin Psychol Med Settings* 2012;19:127–37. <https://link.springer.com/article/10.1007/s10880-011-9274-z>.
159. Courneya KS, Booth CM, Gill S et al. The colon health and life-long exercise change trial: a randomized trial of the National Cancer Institute of Canada clinical trials group. *Curr Oncol* 2008;15:279–85. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601017/>.
160. Courneya KS, Segal RJ, Mackey JR et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicentre RCT. *J Clin Oncol* 2007;25:4396–404. <https://ascopubs.org/doi/10.1200/JCO.2006.08.2024>.
161. Pischke CR, Freda S, Ornish D, Weidner G. Lifestyle changes are related to reductions in depression in persons with elevated coronary risk factors. *Psychol Health* 2010;25:1077–100. <https://pubmed.ncbi.nlm.nih.gov/20204946/>.
162. Rao M, Raghuram N, Nagendra H et al. Anxiolytic effects of a yoga program in early breast cancer patients undergoing conventional treatment: a randomized controlled trial. *Complement Ther Med* 2009;17:1–8. <https://www.sciencedirect.com/science/article/abs/pii/S0965229908000794>.
163. Mock V, Picket M, Ropka ME et al. Fatigue and quality of life outcomes of exercise during cancer treatment. *Cancer Pract* 2001;9:119–27. <https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1523-5394.2001.009003119>.
164. Prasad SM, Eggener SE, Lipsitz SR et al. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. *J Clin Oncol* 2014;32:2471–8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121505>.
165. Lam R, Levitt AJ, Levitan R et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with non-seasonal major depressive disorder. *J Am Med Assoc Psychiatry* 2016;72:2872–81. <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2470681>.
166. Kadan-Lottick NS, Venderwerker LC, Block SD et al. Psychiatric disorders and mental health service use in patients with advanced cancer. *Cancer* 2005;104:2872–81. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459283/>.
167. Kim SA, Roh JL, Lee SA et al. Pre-treatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer. *Cancer* 2015;122:131–40. <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.29693>.
168. Lynch B, Cerin E, Owen N et al. Prospective relationships of physical activity with quality of life among colorectal cancer survivors. *J Clin Oncol* 2008;26:4480–7.
169. Buffart LM, Kalter J, Sweegers MG et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer. An individual patient data meta-analysis of 34 RCTs. *Cancer Treat Rev* 2017;52:91–104. [https://www.cancertreatmentreviews.com/article/S0305-7372\(16\)30135-9/fulltext](https://www.cancertreatmentreviews.com/article/S0305-7372(16)30135-9/fulltext).
170. Thomas R, Marshall C, Williams M, Walker L. Can switching to aromatase inhibitors in tamoxifen intolerant post-menopausal women improve hot flashes, toxicity, qol and mood? *Br J Cancer* 2008;98:1494–9.

171. Arem H, Sorkin M, Cartmel B, Fiellin M *et al.* Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the hormones and physical exercise (HOPE) study. *J Cancer Surviv* 2016;10:654–62. <https://doi.org/10.1007/s11764-015-0511-6> Epub 2016 Jan 19. PMID: 26782031; PMCID: PMC5418660.
172. Waltman NL, Twiss JJ, Ott CD *et al.* The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. *Osteoporos Int* 2010;21:1361–9. <http://link.springer.com/article/10.1007%2Fs00198-009-1083-y>.
173. Newton RU, Galvão DA, Spry N *et al.* Exercise mode specificity for preserving spine and hip BMD in prostate cancer patients. *Med Sci Sports Exerc* 2019;51:607–14.
174. Galster H, Kolb G, Kohsytorz A *et al.* The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. *Thromb Res* 2000;100:381–8. [https://linkinghub.elsevier.com/retrieve/pii/S0049-3848\(00\)00342-X](https://linkinghub.elsevier.com/retrieve/pii/S0049-3848(00)00342-X).
175. Minnella EM, Bosquet-Dion G, Awasthi R *et al.* Multimodal prehabilitation improves functional capacity before and after colorectal surgery for cancer: a five-year research experience. *Acta Oncol* 2017;56:295–300. <https://www.tandfonline.com/doi/full/10.1080/0284186X.2016.1268268>.
176. Myers, Fonda JN, H. The impact of fitness on surgical outcomes: the case for prehabilitation. *Curr Sports Med Rep* 2016;15:282–9. <https://pubmed.ncbi.nlm.nih.gov/27399826/>.
177. Silver JK. Prehabilitation May help mitigate an increase in COVID-19 Peri-pandemic surgical morbidity and mortality. *Am J Phys Med Rehabil* 2020;99:459–63. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253050/>.
178. Van Waart H, Stuiver MM, Van Harten WH *et al.* Design of the Physical exercise during adjuvant chemotherapy effectiveness study (PACES): a randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue. *BMC Cancer* 2010;10:1–12.
179. Irwin ML, Alvarez-Reeves M, Cadmus L *et al.* Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. *Obesity* 2009;17:1534–41. <https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2009.18>.
180. Thomas R. Cancer – the roles of exercise in prevention and progression. *Nutr Food Sci* 2007;37:1–10.
181. Genesis Cancer Care UK Limit. *GenesisCare*. <https://www.genescare.com/uk/>.
182. Royal College of Anaesthetists. *RCoA, Macmillan and NIHR launch Prehabilitation report for people with cancer*. 193. <https://www.rcoa.ac.uk/news/rcoa-macmillan-nihr-launch-prehabilitation-report-people-cancer>.
183. Benke IN, Leitzmann MF, Behrens G, Schmid D. Physical activity in relation to the risk of prostate cancer. A systemic review and meta analysis. *Ann Oncol* 2018;29:1154–79.